TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs
April 08, 2019 08:00 ET
|
Tyme Technologies, Inc.
New oral approach aimed at disrupting cancer metabolismSM-88 is an investigational Cancer Metabolism-Based Therapy (CMBTsTM) that has demonstrated responses across 15 different cancers30 patients...
TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer
April 03, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing...
TYME Announces Dismissal of Class Action Lawsuit
April 01, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) announced the...
Tyme Technologies Announces Pricing of its $12 Million Registered Offering
March 29, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value...
TYME Announces Leadership Team Update
March 18, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, announced a realignment in...
Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
March 11, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that management will...
TYME Continues to Expand Pipeline of Cancer Metabolism-Based Therapies to Potentially Benefit Patients with Difficult-to-Treat Cancers
March 07, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced the addition of...
TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer
February 25, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design...
TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer
February 14, 2019 08:00 ET
|
Tyme Technologies, Inc.
SM-88 therapy did not exhibit typical side effects associated with hormonal castration from androgen-deprivation therapy (ADT)87% of patients (20/23) remained free of radiographic progressionAfter 12...
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
February 11, 2019 07:30 ET
|
Tyme Technologies, Inc.
TYME’s novel metabolic-based investigational cancer therapy, SM-88, demonstrated encouraging results and a well-tolerated safety profile in a preliminary analysis from a Phase II study of patients...